Valvular calcification and left ventricular modifying in peritoneal dialysis patients

Autor:	Emir Kurtalić, Aida Hamzić-Mehmedbašić, Jasminka Džemidžić, Damir Rebić, Senija Rasić
Rok vydání:	2015
Předmět:	Adult Male medicine.medical_specialty medicine.medical_treatment Heart Valve Diseases Critical Care and Intensive Care Medicine End stage renal disease Peritoneal dialysis Young Adult Calcinosis Internal medicine Mitral valve medicine.artery medicine Cardiac valve calcification Humans Prospective Studies cardiovascular diseases Renal replacement therapy Aorta Aged Endothelin-1 business.industry General Medicine Middle Aged equipment and supplies medicine.disease Logistic Models medicine.anatomical_structure Echocardiography Nephrology cardiovascular system Cardiology Kidney Failure Chronic Mitral Valve Female Hypertrophy Left Ventricular business Peritoneal Dialysis Biomarkers Calcification
Zdroj:	Renal Failure. 37:1316-1322
ISSN:	1525-6049 0886-022X
Popis:	Cardiac valve calcification (CVC) and left ventricular (LV) alterations are frequent complication in end-stage renal disease (ESRD). We determined the prevalence of CVC and LV hypertrophy (LVH) in ESRD patients before renal replacement therapy and 12 months after peritoneal dialysis (PD).A prospective longitudinal of 50 incident PD patients was studied. Demographic and clinical data were recorded and blood assayed at baseline and after 1-year of follow-up. CVC and LVH were evaluated by M-mode two-dimensional echocardiography.CVC of the mitral and aortic valves and of both valves were noted in 30, 18 and 10% of patients, respectively. After 12 months of PD regimen, 20% patients had aortic, 24% mitral and 8% had calcification of both valves. After one year of PD, LVH was 62 and 36% in patients with and without CVC, respectively (p 0.05). Endothelin-1 is an independent predictor of CVC at the baseline, while nitric oxide is inversely an independent predictor at the end of follow-up.CVC is associated with LVH in PD patients. These findings identified a potential role for monitored markers to be incorporated into therapeutic strategies aimed at detection and treatment of cardiovascular complications and prevention strategies.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fa1e13a404cdc11e476b50e61a55bd9 https://doi.org/10.3109/0886022x.2015.1073495 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.